# Suzhou Qide Pharmaceutical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-qide-pharmaceutical-technology-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.genequantum.com
- Total disclosed funding: $5.8M
- Latest round: Series C (May 19, 2021)
- Investors on record: 9

## About

Based in Suzhou, China and founded in 2013, Suzhou Qide Pharmaceutical Technology Co., Ltd. develops and provides biopharmaceutical and biotechnology products, as well as reagents and other health-related products. In May 2021, Suzhou Qide Pharmaceutical Technology Co., Ltd. raised an undisclosed amount of series B funding led by new investor and followed by new investor Win Digital Investment Management and new investor HighLight Capital, BrightGene Bio-Medical Technology Co., Ltd.
The company develops new bio-conjugated drugs with differentiated innovation platform technology to provide safer, more effective, and more accessible innovative drugs and treatment solutions for patients around the world. The company focuses on the development of innovative therapies for tumors and other different diseases.
In the future, the company will promote the global clinical development of new-generation ADC innovative drugs with targeted coupling and the expansion of new drug product pipelines.

## Funding rounds

- Series C, May 19, 2021 — PICC Capital Equity Investment, China Life Capital, Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd., Suzhou Wuzhong Biomedical Industrial Park Investment
- Series B, Nov 19, 2020 — HighLight Capital, WinDigital Capital, BrightGene Bio-Medical Technology Co., Ltd.
- Series A, Mar 28, 2017, $5.8M — Oriza Holdings, TF Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- TF Capital — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- WinDigital Capital (https://capitalatlas.ai/funds/windigital-capital) — Series B
- BrightGene Bio-Medical Technology Co., Ltd. — Series B
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series C
- China Life Capital — Series C
- Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd. — Series C
- Suzhou Wuzhong Biomedical Industrial Park Investment — Series C